Iovance reports Q1 net loss $113M; Amtagvi launch strong with 100+ patients enrolled across 40+ ATCs

IOVANCE BIOTHERAPEUTICS, INC.

2024-Q1 EPS reported -$0.42 revenue$715,000

Net loss $113.0M ($0.42 per share) vs $107.4M ($0.50) YoY; revenue $0.7M from Proleukin sales.
Cash, equivalents & investments $362.6M vs $346.3M at Dec 31, 2023; runway into H2 2025.
More than 100 patients enrolled for Amtagvi since Feb 16 FDA approval; ~50 ATCs on track by end of May, 70+ by year-end.
Manufacturing turnaround ~34 days; >75% of enrolled patients covered by private payers.
Regulatory filings for lifileucel on track in EU (Q2 2024), UK/Canada (H2 2024), Australia (2025).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

IOVANCE BIOTHERAPEUTICS, INC. reported financial results for first quarter 2024.

Period: first quarter 2024
Result: reported results

Exact text from the filing

On May 9, 2024, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

IOVANCE BIOTHERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-059322

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.